Follistatin 344

Follistatin 344 (FS344) is a single-chain glycoprotein consisting of 344 amino acids with a molecular weight of approximately 35 kDa. It is the longest and most broadly active isoform of follistatin, generated by inclusion of all exons during transcription of the FST gene located on chromosome 5q11.2. The protein contains an N-terminal signal peptide, an N-terminal domain, three follistatin domains (FSD1-3) each containing a kazal-like serine protease inhibitor motif and an EGF-like module, and a highly acidic C-terminal tail that distinguishes FS344 from the shorter FS315 isoform. Post-translational glycosylation adds approximately 6-8 kDa to the core protein mass.

Follistatin's primary biological function is to bind and neutralize members of the TGF-beta superfamily, most notably activin A, activin B, and myostatin (GDF-8). Binding occurs with high affinity: the dissociation constant (Kd) for the follistatin-myostatin interaction is approximately 0.6 nM, and for activin A approximately 0.1 nM. Follistatin wraps around the ligand dimer using its FSD1 and FSD2 domains, physically blocking access to the ActRII and ActRIIB type II receptors and preventing downstream Smad2/3 phosphorylation. This neutralization effectively removes the brake that myostatin places on skeletal muscle growth.

The biological significance of myostatin inhibition is demonstrated by naturally occurring loss-of-function mutations. Belgian Blue and Piedmontese cattle carry myostatin mutations that produce extreme muscular hypertrophy (double muscling). Bully Whippet dogs with a homozygous myostatin mutation are significantly more muscled than wild-type littermates. Myostatin-knockout mice show 200-300% increases in skeletal muscle mass. Follistatin achieves analogous myostatin blockade pharmacologically rather than genetically.

In a landmark 2009 study published in Proceedings of the National Academy of Sciences (PNAS), Kota et al. demonstrated that AAV-mediated follistatin gene therapy increased quadriceps muscle fiber size by 15% and overall muscle mass by 12% in cynomolgus macaques over a 15-month period, without any exercise intervention. Muscle strength increased proportionally. In the same study, follistatin gene delivery to dystrophic mice significantly improved muscle pathology and function, suggesting therapeutic potential for muscular dystrophies.

Beyond skeletal muscle, follistatin plays important roles in reproductive physiology, liver homeostasis, and fibrosis regulation. Activin A is a major driver of excessive collagen deposition in fibrotic diseases of the liver, lung, and kidney. By neutralizing activin, follistatin reduces Smad2/3-mediated transcription of pro-fibrotic genes including collagen type I, fibronectin, and alpha-smooth muscle actin. Studies in carbon tetrachloride-induced liver fibrosis models showed follistatin overexpression reduced fibrotic area by 40-50%.

Recombinant follistatin 344 is typically produced in Chinese Hamster Ovary (CHO) cells or E. coli expression systems. CHO-derived material is glycosylated and closer to the native human protein, while E. coli-derived material is non-glycosylated but retains biological activity. Product identity is confirmed by SDS-PAGE (band at ~35-38 kDa under reducing conditions), Western blot with anti-follistatin antibody, and ELISA-based quantification. Bioactivity is verified by activin A neutralization assay. Lyophilized follistatin should be stored at -20 degrees C or below and reconstituted with sterile water or PBS. Reconstituted protein should be stored at 2-8 degrees C and used within 7 days, or aliquoted and frozen at -20 degrees C.

Follistatin has been administered to humans in the context of gene therapy clinical trials for Becker muscular dystrophy (Mendell et al., Molecular Therapy 2015). In a Phase 1/2a trial, intramuscular injection of AAV1-follistatin improved distance walked on the 6-minute walk test in all treated patients, with no serious adverse events related to follistatin overexpression at 2-year follow-up. Circulating follistatin levels are naturally regulated by activin in a feedback loop, and transient elevations in exogenous follistatin have not been associated with significant endocrine disruption in published studies.